check_circleStudy Completed

Renal Artery Stenosis

Bayer Identifier:

90940

ClinicalTrials.gov Identifier:

NCT00310557

EudraCT Number:

Not Available

EU CT Number:

Not Available
Magnevist® Injection-enhanced MRA compared to non contrast MRA for the detection of stenosis of the renal arteries

Trial purpose

The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the renal arteries. The results will be compared to the results of MRI taken without Magnevist and with the results of your X-ray angiography.

Key Participants Requirements

Sex

Both

Age

18 Years
  • - Has known or suspected renal artery disease - Is scheduled for X-ray angiography
  • - Has any contraindication to magnetic resonance imaging - Is scheduled for any procedure before the X-ray angiography - Had previously had stents placed bilaterally in the region to be imaged

Trial summary

Enrollment Goal
116
Trial Dates
December 2003 - December 2004
Phase
Phase 3
Could I Receive a placebo
No
Products
Magnevist (Gadopentetate Dimeglumine, BAY86-4882)
Accepts Healthy Volunteer
No

Primary Outcome

  • Accuracy, sensitivity and specificity based on quantitative assessment of stenosis
    date_rangeTime Frame:
    Image creation after injection - evaluation at blind read
    enhanced_encryption
    Safety Issue:
    None

Secondary Outcome

  • Diagnostic confidence
    date_rangeTime Frame:
    At blinded and/or open label read of images
    enhanced_encryption
    Safety Issue:
    None
  • Accuracy, sensitivity, and specificity based on visual assessment of stenosis assesses
    date_rangeTime Frame:
    At blinded and/or open label read of images
    enhanced_encryption
    Safety Issue:
    None
  • Difference in degree of stenosis
    date_rangeTime Frame:
    At blinded and/or open label read of images
    enhanced_encryption
    Safety Issue:
    None
  • Other diagnostic findings
    date_rangeTime Frame:
    At blinded and/or open label read of images
    enhanced_encryption
    Safety Issue:
    None
  • Localisation matching of maximum stenosis
    date_rangeTime Frame:
    At blinded and/or open label read of images
    enhanced_encryption
    Safety Issue:
    None
  • Image quality
    date_rangeTime Frame:
    At blinded and/or open label read of images
    enhanced_encryption
    Safety Issue:
    None
  • Image evaluability and presence of artifacts
    date_rangeTime Frame:
    At blinded and/or open label read of images
    enhanced_encryption
    Safety Issue:
    None
  • Proportions of correctly categorised arteries with regard to maximum stenosis
    date_rangeTime Frame:
    At blinded and/or open label read of images
    enhanced_encryption
    Safety Issue:
    None
  • Number of evaluable arteries
    date_rangeTime Frame:
    At blinded and/or open label read of images
    enhanced_encryption
    Safety Issue:
    None
  • Patient management
    date_rangeTime Frame:
    From baseline to 24 hours follow-up
    enhanced_encryption
    Safety Issue:
    None
  • Safety
    date_rangeTime Frame:
    From baseline to 24 hours follow-up
    enhanced_encryption
    Safety Issue:
    None

Trial design

Multicenter, open-label study of the safety (open-label) and efficacy (open-label and blinded reader) of a single administration of approximately 0.1 mmol/kg of Magnevist® Injection-enhanced magnetic resonance arteriography (MRA) and 2-dimensional-time-of-flight (2D-TOF) MRA in patients with known or suspected renal artery disease undergoing MRA of the renal arteries with intra-arterial digital subtraction arteriography (i.a. DSA) as the standard of reference
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Diagnostic
Allocation
Non-randomized
Blinding
Open Label
Assignment
Single Group Assignment
Trial Arms
1

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to Bayer Healthcare products.